550-81-2 Usage
Uses
Used in Pharmaceutical Industry:
Amopyroquine is used as an antimalarial agent for treating malaria. It exhibits potent activity against Plasmodium parasites, which are responsible for causing malaria. Amopyroquine's effectiveness in combating malaria makes it a valuable asset in the fight against this life-threatening disease.
Additionally, due to its chemical properties as a pale yellow solid, Amopyroquine may also be used in the development of pharmaceutical formulations and drug delivery systems to improve the bioavailability and efficacy of the drug in treating malaria.
Check Digit Verification of cas no
The CAS Registry Mumber 550-81-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,5 and 0 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 550-81:
(5*5)+(4*5)+(3*0)+(2*8)+(1*1)=62
62 % 10 = 2
So 550-81-2 is a valid CAS Registry Number.
InChI:InChI=1/C20H20ClN3O/c21-15-3-5-17-18(7-8-22-19(17)12-15)23-16-4-6-20(25)14(11-16)13-24-9-1-2-10-24/h3-8,11-12,25H,1-2,9-10,13H2,(H,22,23)
550-81-2Relevant academic research and scientific papers
ANTIVIRAL DRUG FOR SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME
-
Paragraph 0067-0070; 0077-0079, (2020/01/10)
The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.)
NOVEL AMODIAQUINE ANALOGS AND METHODS OF USES THEREOF
-
Paragraph 0029; 0030; 0088; 0089; 0090, (2018/11/10)
Described herein are pharmaceutical compositions capable of blocking entry of a virus into a host cell and containing one or more compounds of the general formula I or a pharmaceutically acceptable derivative thereof and methods of treatment or prophylact
